STOCK TITAN

Kronos Bio Inc - KRON STOCK NEWS

Welcome to our dedicated news page for Kronos Bio (Ticker: KRON), a resource for investors and traders seeking the latest updates and insights on Kronos Bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Kronos Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Kronos Bio's position in the market.

Rhea-AI Summary
Kronos Bio will present a clinical update on the Phase 1/2 trial of KB-0742 at the 2024 ASCO Annual Meeting. The study update will focus on the oral CDK9 inhibitor KB-0742 in relapsed or refractory transcriptionally addicted advanced solid tumors. The trial aims to assess safety, tolerability, and preliminary efficacy of KB-0742 at increasing dose levels. The presentation will be led by Brian A. Van Tine, M.D., Ph.D., from Washington University in St. Louis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
conferences clinical trial
-
Rhea-AI Summary
Kronos Bio, Inc. reports positive business progress and financial results for Q4 2023, with promising updates on KB-0742 and KB-9558. The company expects to clear 80mg dosing schedule for KB-0742 by Q3 2024 and commence the first-in-human study for KB-9558 in H1 2025. With $175.0 million in cash as of December 31, 2023, Kronos Bio anticipates sufficient resources to fund operations until H2 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
-
Rhea-AI Summary
Kronos Bio, Inc. announces a restructuring plan to optimize resources and extend cash runway, focusing on advancing KB-0742 and KB-9558. The plan includes a 21% reduction in force to streamline operations and maximize the potential of their pipeline. The Company aims to explore an extended dosing schedule for KB-0742 and expects to share topline data from the expansion cohort in the first half of 2025. IND-enabling studies for KB-9558 are set to complete in 2024 with a first-in-human study anticipated in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Kronos Bio, Inc. (Nasdaq: KRON) announces the selection of three abstracts for presentation at the AACR annual meeting, highlighting the effectiveness of targeting p300's enzymatic KAT domain in downregulating IRF4, a crucial transcription factor in multiple myeloma. The company's innovative approach shows promising antiproliferative effects against myeloma cells.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.65%
Tags
conferences
-
Rhea-AI Summary
Kronos Bio, Inc. (Nasdaq: KRON) will participate in the 44th Annual Cowen Health Care Conference, with the CEO joining a panel discussion on Novel Oncology Targets. The event will take place from March 4-6, 2024, in Boston, Massachusetts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.15%
Tags
none
-
Rhea-AI Summary
Kronos Bio, Inc. has announced a streamlined leadership structure, eliminating three executive officer roles and appointing a new Executive Leadership team. The company aims to focus on pipeline advancement and align with current operating needs. The new leadership structure includes a Senior Vice President for Research and Development, a Senior Vice President for Clinical Development, a Senior Vice President for Corporate Strategy and Portfolio Management, and a Senior Vice President for Corporate Operations and Legal. The changes are designed to optimize resources and efficiently deliver on business objectives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
none
Rhea-AI Summary
Kronos Bio, Inc. (Nasdaq: KRON) provides an update on its pipeline, including the completion of the phase 1b portion of the lanraplenib study, the designation of a new development candidate KB-9558, and the progress of its first development candidate KB-0742. The company also maintains its expected cash runway into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.01%
Tags
none
-
Rhea-AI Summary
Kronos Bio, Inc. (Nasdaq: KRON) announced the participation of key executives in a fireside chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference. The event will be held on December 6, 2023, at 11:00 a.m. ET, with a live audio webcast available on the company's website. The participation of Dr. Jorge DiMartino and Dr. Charles Lin signifies the company's commitment to advancing precision oncology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
none
-
Rhea-AI Summary
Kronos Bio, Inc. (KRON) to participate in fireside chat at 35th Annual Piper Sandler Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.15%
Tags
none
Rhea-AI Summary
Kronos Bio, Inc. (Nasdaq: KRON) reported positive preliminary data from the Phase 1 dose escalation portion of the KB-0742 study at AACR-NCI-EORTC and CTOS conferences. This data showed on-mechanism, single agent anti-tumor activity and a manageable safety profile in pre-treated patients with transcriptionally addicted solid tumors. The company also announced a plan to optimize resource allocation, restructure, and contain costs, extending its cash runway into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
Kronos Bio Inc

Nasdaq:KRON

KRON Rankings

KRON Stock Data

67.91M
43.75M
19.59%
44.68%
1.11%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
San Mateo

About KRON

kronos bio is dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. leveraging industry-leading research into high-throughput screening strategies for chemical modulators of transcription factors and other challenging targets in oncology, kronos utilizes its small molecule microarray (smm) platform and extensive know-how in biological assay development to pursue novel therapies against some of the most important and intractable targets in cancer research.